# New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Canonical URL: https://biopharmsignal.com/news/ASND/new-insights-trial-of-transconr-hgh-lonapegsomatropin-in-turner-syndrome-demonstrated-comparable-efficacy-and-safety-to-daily-somatropin-at-week-52
Ticker: ASND
Company: Ascendis Pharma
Source: Ascendis Pharma
Published: 2026-03-17 12:30 EST
Original Source URL: https://investors.ascendispharma.com
## Summary

- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children  - TransCon hGH showed a safety and tolerability profile comparable to daily somatropin with no occurrences of slipped capital femoral epiphysis

## Article Body
- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children  - TransCon hGH showed a safety and tolerability profile comparable to daily somatropin with no occurrences of slipped capital femoral epiphysis
## Recent Company News
- 2026-06-30 12:30 EST — [Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial](https://biopharmsignal.com/news/ASND/children-with-achondroplasia-treated-with-transcon-cnp-showed-continued-improvem-93d02f62) — Source: Ascendis Pharma
- 2026-06-26 20:01 EST — [Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®](https://biopharmsignal.com/news/ASND/ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1-d1ad8aa7) — Source: Ascendis Pharma
- 2026-06-25 20:01 EST — [Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026](https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-achondroplasia-at-iccbh-2026-cf687b9b) — Source: Ascendis Pharma
- 2026-06-13 20:00 EST — [Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/phase-3-data-show-transcon-pth-replicated-systemic-actions-of-endogenous-pth-thr-c45e7bfc) — Source: Ascendis Pharma
- 2026-06-11 20:01 EST — [5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/5-year-phase-2-data-show-transcon-pth-replicated-systemic-actions-of-endogenous--57728427) — Source: Ascendis Pharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)